These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
563 related articles for article (PubMed ID: 30073633)
1. Niraparib: A Review in Ovarian Cancer. Heo YA; Duggan ST Target Oncol; 2018 Aug; 13(4):533-539. PubMed ID: 30073633 [TBL] [Abstract][Full Text] [Related]
2. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572 [TBL] [Abstract][Full Text] [Related]
3. Niraparib: First Global Approval. Scott LJ Drugs; 2017 Jun; 77(9):1029-1034. PubMed ID: 28474297 [TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751 [TBL] [Abstract][Full Text] [Related]
5. Niraparib for the treatment of ovarian cancer. Kanjanapan Y; Lheureux S; Oza AM Expert Opin Pharmacother; 2017 Apr; 18(6):631-640. PubMed ID: 28299955 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768 [TBL] [Abstract][Full Text] [Related]
9. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU; Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354 [TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. Ni J; Cheng X; Zhao Q; Dai Z; Xu X; Guo W; Gu H; Zhou R; Wang Y; Chen X J Ovarian Res; 2021 May; 14(1):68. PubMed ID: 33993885 [TBL] [Abstract][Full Text] [Related]
11. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273 [TBL] [Abstract][Full Text] [Related]
12. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079 [TBL] [Abstract][Full Text] [Related]
13. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244 [TBL] [Abstract][Full Text] [Related]
14. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788 [TBL] [Abstract][Full Text] [Related]
15. Niraparib Slows Ovarian Cancer Progression. Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860 [TBL] [Abstract][Full Text] [Related]
16. The role of niraparib for the treatment of ovarian cancer. Ethier JL; Lheureux S; Oza AM Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239 [TBL] [Abstract][Full Text] [Related]
17. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410 [TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000 [TBL] [Abstract][Full Text] [Related]
19. Niraparib for the treatment of ovarian cancer. Essel KG; Moore KN Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447 [TBL] [Abstract][Full Text] [Related]
20. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial. Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X Trials; 2024 May; 25(1):301. PubMed ID: 38702828 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]